sapanisertib + docetaxel

**Sapanisertib + docetaxel** is an experimental combination therapy involving sapanisertib, a **small molecule inhibitor of mTOR complex 1 and 2 (mTORC1/2)**, and docetaxel, a **chemotherapy agent in the taxane class**. Sapanisertib acts by inhibiting the mTOR pathway, an essential driver of cellular growth, proliferation, and survival, which is frequently altered in cancers. Docetaxel disrupts cell division by promoting microtubule stabilization, leading to apoptosis in rapidly dividing tumor cells. The combination is being tested for its potential to overcome resistance to taxane chemotherapy by dual targeting of mTOR and cytoskeletal mechanisms.